Completing data — refresh the page later to see the latest
1185039-30-8Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1BOVGTQGAOIONJV-UHFFFAOYSA-NGliclazide is a N-sulfonylurea. It has a role as a hypoglycemic agent, a radical scavenger and an insulin secretagogue.
1185039-30-8CHEMBL427216Pharmaceuticals -> Used in Switzerland
Pharmaceuticals
1.90e-01 g/L
42.6 [ug/mL] (The mean of the results at pH 7.4)
180-182
181 °C
164.21 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
178 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
This chemical does not meet GHS hazard criteria for 77.5% (55 of 71) of all reports.
Warning
H302 (12.7%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 71 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Gliclazide
DILI Positive
Oral
DOI:10.1016/j.drudis.2019.09.022
A10BB09
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
A10BB09
Based on the pharmacological properties, gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates β cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.
Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.
Extensively metabolized in the liver. Less than 1% of the orally administered dose appears unchanged in the urine. Metabolites include oxidized and hydroxylated derivates, as well as glucuronic acid conjugates.
Gliclazide has known human metabolites that include 7-hydroxy-gliclazide, Methylhydroxygliclazide, and 6-hydroxy-gliclazide.
Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration.
CHEBI:31654Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in the feces (10-20%).
UsesA sulfonylurea hypoglycemic agent. Used as an antidiabetic.
UsesAs a sulfonylurea hypoglycemic agent, Gliclazide-d4 can be used as an antidiabetic.